This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Health Stocks in Motion

Updated from 3:33 p.m. EDT

Shares of Gentiva Health Services (GTIV) were among the worst-performing health-related stocks Thursday, falling 16.4% after the company posted first-quarter earnings and sales that disappointed Wall Street.

The provider of home health services posted earnings of $4.1 million, or 17 cents a share, on sales of $207.1 million. Analysts surveyed by Thomson First Call were expecting earnings of 21 cents a share on sales of $217.8 million. A year ago the company reported adjusted earnings of $4.3 million, or 16 cents a share, on sales of $205.9 million, which excludes special items.

Looking ahead, Gentiva now expects 2005 earnings of 75 cents to 83 cents a share, up from previous guidance of 72 cents to 80 cents a share. Part of the company's upward revision is due to a delay in the implementation of accounting rules on stock-based compensation, which will now go into affect during fiscal 2006, instead of the second half of 2005. The accounting change would have increased expenses by 6 cents to 8 cents a share.

The company also said that its outlook is based on the acquisition of Heritage Home Care Services, a conservative view regarding sales from its Cigna relationship -- based on first-quarter results -- and the company's decision to invest in clinical capacity and branch operations. Gentiva backed its 2005 sales estimate of $870 million to $890 million. Analysts are expecting earnings of 83 cents a share on sales of $893 million. Shares traded down $3.42 to $17.41.

Bentley Pharmaceuticals (BNT) rose 22.6% after the company posted first-quarter results that easily topped expectations. The drug delivery company earned $2.2 million, or 10 cents a share, on sales of $24.2 million. Analysts were expecting earnings of 5 cents a share on sales of $20.1 million. Results were helped by sales volume growth in Spain, a strengthening of the euro against the dollar and continued growth in pharmaceutical sales to licensees, both in Spain and outside of Spain. A year ago the company earned $800,000, or 4 cents a share, on sales of $17.3 million. Shares traded up $1.71 to $9.29.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,424.85 +162.29 1.00%
S&P 500 1,862.31 +19.33 1.05%
NASDAQ 4,086.2250 +52.0640 1.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs